The size of the global cytokine-based therapies and inhibitors market is estimated to grow at a healthy CAGR during the forecast period.
Cytokines are the molecular messengers that allow communication with the immune system cells to generate a coordinated, robust but self-limited response to the targeted antigen. Cytokines provide various benefits; unlike chemical drugs, a specific protein that mediates the inflammatory process can be inhibited. Cytokine inhibitors include antagonists, soluble receptors, cytokine-binding proteins, and the cytokine that blocks other cytokines. The treatment for immune-mediated medical illnesses, including cancer and viral infections, can be done using Immunomodulatory, anti-viral, antiproliferative properties, cytokine interferon-alpha interleukin (IL). The cytokine-based therapies can provide novel treatments for cancer, autoimmune diseases, and many types of infectious diseases. Various factors have limited the clinical potential of cytokines as drugs. FDA partnership was made with the New York Academy of Sciences to host a forum to discuss practical ways to harness the clinical potential of cytokines and cytokine antagonists as therapeutic agents.
Cytokine-based therapies have the potential to provide treatments for autoimmune diseases and cancer. Intercellular messengers activate signaling pathways in virtually all cell types. Rising research and development for understanding the mechanics and technological advancements in the immunological and therapeutics applications are anticipated to propel the market growth of the cytokine-based Therapies and Inhibitors Market. Increasing interest in harnessing the immune system to eradicate cancer will crease demand for the market. Vast signaling networks to develop cancer treatments are expected to raise market growth. Several animal tumor model studies have displayed that cytokines have a broad anti-tumor activity translated into several cytokine-based approaches for cancer therapy which is expected to drive market growth. Cytokines are finding growing acceptance in cancer therapy all over the world.
The Cytokine Based Therapies and Inhibitors Market has some restraining factors that are restraining market growth, such as the scarcity of skilled professionals for cytokine treatments for autoimmune diseases and cancer across the world; the high cost of therapies is expected to impede the market growth.
REPORT METRIC |
DETAILS |
Market Size Available |
2024 to 2029 |
Base Year |
2024 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Type, Therapeutic Application, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Market Leaders Profiled |
Some of the prominent companies leading the global cytokine-based therapies and inhibitors market profiled in this report are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson, and Amgen Inc. |
Based on the type, the interleukins segment is expected to dominate the global cytokine-based therapies and inhibitors market during the forecast period. Interleukins are a group of cytokines that were first seen to be expressed by white blood cells. Interleukins regulate cell growth, differentiation, and mobility, which are essential in stimulating immune responses like inflammation. The increasing global prevalence of autoimmune disorders, increasing geriatric population, and advanced technologies in novel interleukins inhibitors are projected to increase the market growth.
Based on the therapeutic application, the inflammatory and immune disorders segment accounted for the largest share in the global market during the forecast period. The sign of an autoimmune disease is inflammation which causes redness, pain, and swelling. The disorders also have flare-ups when they get worse and are in remission. An increase in the autoimmune system incidence, a rise in the adoption of autoimmune disease therapeutics, and growing R&D activities to develop ideal therapeutics are the major driving factors of the inflammatory and immune disorders market.
Geographically, North America leads the global cytokine-based therapies and inhibitors market due to many companies in Cytokine Based Therapies and Inhibitors and increasing government investments. The North American Cytokine Based Therapies and Inhibitors Market growth is majorly driven by the factors such as the increasing prevalence of cancer. According to the American cancer society, it was estimated there were 1,762,450 new cancer cases and 606,880 diagnosed cancer deaths in the United States, which are anticipated to rise in the future. Moreover, increasing R&D activities of cancer therapies with lesser side effects are expected to create demand for cytokine-based treatments through which market expansion is possible.
In 2023, the European market accounted for a substantial share globally and was estimated to register a healthy CAGR during the market forecast period. The market growth can be increased by the factors such as growing interest among people in harnessing the immune system to eradicate cancer.
The Asia Pacific is the fastest-growing market segment due to the growing awareness and increasing collaborations with western companies in China and the well-established biotechnology industries in Japan.
The Latin American market is expected to have steady growth with an increasing compound annual growth rate (CAGR). The players are technological advancements in immunological and therapeutics applications and are anticipated to propel cytokine-based market growth.
Middle East Africa held a moderate share of the Cytokine Based Therapies and Inhibitors Market. The market had a portion of the global market in 2020. However, Middle East Africa is projected to increase its growth during the forecast period.
Some of the prominent companies leading the global cytokine-based therapies and inhibitors market profiled in this report are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson, and Amgen Inc.
By Type
By Therapeutic Application
By Region
Frequently Asked Questions
The growing prevalence of autoimmune diseases, cancer, and infectious diseases, as well as advancements in cytokine-based drug development boost the market growth.
AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., and Roche Holding AG are some of the major companies in the market.
North America is the largest market for cytokine-based therapies and inhibitors, followed by Europe and Asia Pacific.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region